S. Lu

M. Tsuboi, R. Herbst, F. Shepherd, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adverse Effects of Combined Tyrosine Kinase Inhibitors.

Shun Lu, Zi-ming Li, S. Lu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Jun Ma, Yi-long Wu, Q. Xiu, 2011, The Lancet. Oncology.

Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.

Joe Y. Chang, T. de Baère, S. Senan, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Shun Lu, X. Ai, Jie-jun Wang, 2018, BMC Cancer.

FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer

W. Xia, Shun Lu, X. Niu, 2018, Oncogene.

Integrated discovery of FOXO1-DNA stabilizers from marine natural products to restore chemosensitivity to anti-EGFR-based therapy for metastatic lung cancer.

Xiangyun Ye, Ruijun Liu, Shun Lu, 2017, Molecular bioSystems.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

E. Felip, A. Ardizzoni, Y. Min, 2021, EClinicalMedicine.

Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge

Yong-feng Yu, Ying Yang, S. Lu, 2020, Science China Life Sciences.

Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge

Ying Yang, Shun Lu, Yong-feng Yu, 2020, Science China Life Sciences.

FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.

W. Xia, Min Lu, Shun Lu, 2021, Cellular immunology.

XBP 1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3 D culture

M. Liao, Shun Lu, Yi Zhao, 2017 .

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

M. Tsuboi, Jie He, R. Herbst, 2020, The New England journal of medicine.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

A Randomized Controlled Study of rhTPO and rhIL-11 for the Prophylactic Treatment of Chemotherapy-Induced Thrombocytopenia in Non-Small Cell Lung Cancer

Qiong Zhao, Li Liu, Yunhua Xu, 2018, Journal of Cancer.

Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma

Shun Lu, Yuchen Han, H. Jian, 2019, Anti-cancer drugs.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

K. Syrigos, E. Felip, J. Soria, 2018, JAMA oncology.

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology

Yangqiu Li, Yingyong Hou, Ying Cheng, 2019, Cancer biology & medicine.

A Study of Ethnic Differences in TGF&bgr;1 Gene Polymorphisms and Effects on the Risk of Radiation Pneumonitis in Non–Small-Cell Lung Cancer

Yun Liu, Shun Lu, Daizhan Zhou, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.

Shun Lu, Zi-ming Li, S. Lu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

N. Girard, Keunchil Park, L. Paz-Ares, 2018 .

NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy

P. Ji, L. Xia, Shun Lu, 2021, Cancer science.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma

W. Xia, L. Xia, Shun Lu, 2021, Translational oncology.

Peripheral CD4+ T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer

Sheng He, Mingjiao Sun, L. Xia, 2021, Science China Life Sciences.

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

N. Yang, K. Ying, Zhijie Wang, 2021, JAMA oncology.

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing

Shun Lu, W. Ji, Yong-feng Yu, 2021, Annals of translational medicine.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.

Yueping Jin, Huajun Zheng, L. Xia, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

N. Girard, J. Taube, S. Broderick, 2022, The New England journal of medicine.

BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.

H. Zhang, Yi-long Wu, B. Han, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10

Shun Lu, X. Ai, Yingjia Sun, 2015, Oncotarget.

Regulation of β-catenin-mediated esophageal cancer growth and invasion by miR-214.

Shun Lu, Yunhua Xu, S. Lu, 2015, American journal of translational research.

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer

Hongyan Chen, L. Xia, Shun Lu, 2021, Frontiers in Immunology.

Exosomal miR‐499a‐5p promotes cell proliferation, migration and EMT via mTOR signaling pathway in lung adenocarcinoma

W. Xia, Shun Lu, W. Ji, 2019, Experimental cell research.

The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

Shun Lu, Yingjia Sun, H. Husain, 2021, Translational lung cancer research.

Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Zhijian Sun, Yiping Zhang, Z. Song, 2021, Clinical Cancer Research.

Reciprocal regulatory mechanism between miR-214-3p and FGFR1 in FGFR1-amplified lung cancer

W. Xia, Ying Yang, Shun Lu, 2019, Oncogenesis.

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

Chengping Hu, Gang Wu, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis

Shun Lu, Yong-feng Yu, Jingqi Zhuang, 2017, Oncotarget.

Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment

Yun Liu, Zhen Zhou, M. Liao, 2017, Clinical Cancer Research.

MicroRNA-214-3p inhibits the stem-like properties of lung squamous cell cancer by targeting YAP1

Ying Yang, Shun Lu, Zi-ming Li, 2020, Cancer Cell International.

The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.

W. Xia, Ying Yang, Shun Lu, 2018, Cancer letters.

Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients

W. Xia, Q. Luo, Q. Tan, 2016, Oncotarget.

TERT Polymorphism rs2736100-C Is Associated with EGFR Mutation–Positive Non–Small Cell Lung Cancer

Christopher I Amos, Murray Favus, Hongwei Wang, 2015, Clinical Cancer Research.

Acetylcholine receptor pathway in lung cancer: New twists to an old story.

Shun Lu, X. Niu, S. Lu, 2014, World journal of clinical oncology.

GPC5 rs2352028 Polymorphism and Risk of Lung Cancer in Han Chinese

Yun Liu, Yonglan Zheng, Shun Lu, 2012, Cancer investigation.

Association of the CHRNA3 Locus with Lung Cancer Risk and Prognosis in Chinese Han Population

Yun Liu, M. Liao, Shun Lu, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.

W. Xia, L. Xia, X. Niu, 2022, Clinical and Experimental Immunology.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.

D. Carbone, E. Felip, L. Paz-Ares, 2021, The Lancet. Oncology.

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Prasad Adusumilli, Young Tae Kim, Ugo Pastorino, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

K. Syrigos, E. Felip, J. Soria, 2015, The Lancet. Oncology.

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial

Zhen Zhou, Shun Lu, X. Ai, 2021, BMC Cancer.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib

Shun Lu, S. Lu, 2019, OncoTargets and therapy.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

K. Syrigos, E. Felip, J. Soria, 2017, Lung cancer.

[Genome wide association study on lung cancer.].

Shun Lu, X. Ai, Xiaomin Niu, 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2015 .

Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).

Yi-long Wu, Q. Xiu, Chengping Hu, 2012 .

[Research status on targeted therapy for squamous cell lung cancer].

Shun Lu, Hong Yuan, S. Lu, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies.

Shun Lu, X. Niu, Zhiwei Chen, 2011, Mutagenesis.

Landscape and Predictive Significance of the Structural Classification of EGFR Mutations in Chinese NSCLCs: A Real-World Study

L. Xia, Shun Lu, X. Niu, 2022, Journal of clinical medicine.

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Haidong Wang, Shun Lu, X. Ai, 2014, Amino Acids.

The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis

Shun Lu, X. Niu, D. Ding, 2014, OncoTargets and therapy.

EGFR L861Q mutation is a frequent feature of pulmonary mucoepidermoid carcinoma

Q. Luo, Shun Lu, Hui-quan Gao, 2012, Journal of Cancer Research and Clinical Oncology.

Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer

Jianren Gu, B. Shi, Zonghai Li, 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

Impact of Lymph Node Dissection on Survival and Tumor Recurrence for Patients with Resected cT1-2N0 Small Cell Lung Cancer

Q. Luo, Shun Lu, Yuan Liu, 2022, Annals of Surgical Oncology.

Lung squamous cell carcinoma: A postoperative recurrence analysis of keratinizing and nonkeratinizing subtypes.

Rongrong Chen, Shun Lu, Lei Zhu, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.

Zonghai Li, M. Liao, Shun Lu, 2012, Lung cancer.

Research progress of positive ALK fusion gene non-small cell lung cancer

Shun Lu, Yong-feng Yu, Ying-lei Liu, 2019 .

Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Danyi Wen, Shun Lu, Jie Zhang, 2018, Cancer communications.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer

Jae Cheol Lee, Jih-Hsiang Lee, F. Siddiqui, 2017, Oncotarget.

LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

Everolimus and zoledronic acid--a potential synergistic treatment for lung adenocarcinoma bone metastasis.

Shun Lu, Xiaohua Yang, shunfang yang, 2014, Acta biochimica et biophysica Sinica.

Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.

Shun Lu, M. Ye, Jie Zhang, 2016, Pharmacogenomics.

Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma

J Zhang, Zhen Zhou, Shun Lu, 2019, Thoracic cancer.

A 3D Ex Vivo Tumor‐Immune Coculture System Mimicking In Vivo Tumor Environmental Stress on CD8+ T Cells Exhaustion

Ying Chen, W. Cui, Zhen Wang, 2023, Advanced biology.

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

Yao Lu, Shun Lu, S. Lu, 2022, Cancers.

PAK5 promotes the cell stemness ability by phosphorylating SOX2 in lung squamous cell carcinomas.

W. Xia, Ying Yang, Shun Lu, 2020, Experimental cell research.

FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway

W. Xia, Shun Lu, Zi-ming Li, 2016, Oncotarget.

17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway

Q. Luo, Shun Lu, X. Niu, 2015, Journal of cellular and molecular medicine.

The effects of cetuximab alone and in combination with endostatin on vascular endothelial growth factor and interleukin-8 expression in human lung adenocarcinoma cells.

Shun Lu, Zong-hai Li, Zhiwei Chen, 2009, Current therapeutic research, clinical and experimental.

βKlotho is identified as a target for theranostics in non-small cell lung cancer

W. Xia, Shun Lu, W. Ji, 2019, Theranostics.

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression

Zhen Zhou, M. Liao, Q. Luo, 2017, Oncotarget.

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Zhen Zhou, G. Jiang, Shun Lu, 2019, Cancer management and research.

Clinic application of tissue engineered bronchus for lung cancer treatment.

W. Weder, Q. Luo, Q. Tan, 2017, Journal of thoracic disease.

Transforming growth factor-β1-induced epithelial to mesenchymal transition increases mitochondrial content in the A549 non-small cell lung cancer cell line.

Yunhua Xu, S. Lu, 2015, Molecular medicine reports.

Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing

Shun Lu, J. Qian, Lan Shen, 2021, International journal of medical sciences.

The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients

Jin-Ji Yang, K. Lu, Jie Hu, 2019, Cancer biology & therapy.

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer

Shun Lu, D. Ding, Yong-feng Yu, 2020, Cancer medicine.

Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma.

Shun Lu, X. Ye, Yong-feng Yu, 2019, Journal of thoracic disease.

Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.

Xue Wu, Y. Shao, Q. Ou, 2019, Lung cancer.

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China

Shun Lu, Yong-feng Yu, H. Ren, 2018, PloS one.

Results of PROFILE 1029, a Phase III Comparison of First‐Line Crizotinib versus Chemotherapy in East Asian Patients with ALK‐Positive Advanced Non–Small Cell Lung Cancer

T. Mok, Yi-long Wu, K. Wilner, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1‐Rearranged Non–Small Cell Lung Cancer

Jia Huang, Shun Lu, Jie Zhang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, EGFR-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study

Ying Cheng, Yi-long Wu, Zhi-yong Ma, 2020 .

An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.

Shun Lu, X. Ai, S. Shen, 2015, Biochimie.

AZD0530 sensitizes drug‐resistant ALK‐positive lung cancer cells by inhibiting SRC signaling

Shun Lu, Yi Zhao, Yi Yang, 2017, FEBS open bio.

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Zhen Zhou, G. Jiang, Zhengping Ding, 2019 .

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer

Ying Yang, Shun Lu, Tingting Lu, 2020, Cell adhesion & migration.

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).

Ying Cheng, T. Mok, Yi-long Wu, 2021, Lung cancer.

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer

Baolan Li, Wei Li, Chengping Hu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer

Zhen Zhou, M. Liao, Q. Luo, 2013, OncoTargets and therapy.

Metformin Inhibits Esophagus Cancer Proliferation through Upregulation of USP7

Shun Lu, Yunhua Xu, S. Lu, 2013, Cellular Physiology and Biochemistry.

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer

Zhen Zhou, Q. Luo, Shun Lu, 2012, Journal of experimental & clinical cancer research : CR.

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC

Shun Lu, Yong-feng Yu, S. Lu, 2023, Therapeutic advances in medical oncology.

Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Yiping Zhang, S. Cai, C. Xie, 2022, BMC Medicine.

Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer

Fen Wang, Zhen-ke Wen, Shun Lu, 2021, Annals of translational medicine.

A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer.

Bingbing Ni, Jiancheng Yang, L. Xia, 2021, American journal of translational research.

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

X. Yi, Xiaohua Hu, Jiexia Zhang, 2020, Clinical Cancer Research.

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

N. Girard, Keunchil Park, L. Paz-Ares, 2020, Frontiers in Oncology.

Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial.

C. Chiu, T. Hsia, D. Camidge, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma

Shun Lu, Zhi Shang, X. Niu, 2019, Journal of Molecular Medicine.

Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.

Ying Cheng, Yi-long Wu, B. Han, 2019, Lung cancer.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.

Shun Lu, Zhiwei Chen, Yong-feng Yu, 2011, Chinese medical journal.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients

J. Heath, Jungwoo Kim, Wei Wei, 2017, Proceedings of the National Academy of Sciences.

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Shun Lu, M. Ye, F. Tan, 2016, Oncotarget.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Yi-long Wu, B. Peil, Wei Li, 2018, OncoTargets and therapy.

The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging

Jianping Zhang, Jianping Zhang, Shun Lu, 2019, Oncology reports.

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status

Wei Li, C. Bai, Wei Li, 2017, Scientific Reports.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Jie Yang, M. Salto‐Tellez, J. Shih, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

L. Sequist, K. O'Byrne, T. Mok, 2017, The Patient - Patient-Centered Outcomes Research.

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer (INFORM; C-TONG 0804)

Ying Cheng, B. Han, Yunpeng Liu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence

J. Shih, C. Liam, Shun Lu, 2021, Advances in Therapy.

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.

Ying Cheng, B. Han, Yunpeng Liu, 2012, The Lancet. Oncology.

Chinese pediatric and adolescent primary tracheobronchial tumors: a hospital-based study

Shun Lu, Zhiwei Chen, H. Jian, 2011, Pediatric Surgery International.

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic

G. Scagliotti, E. Smit, A. Dingemans, 2020, Journal of Thoracic Oncology.

Maintenance therapy for NSCLC: Consensus and controversy

Yong-feng Yu, S. Lu, Yong-feng Yu, 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A Cost-Effectiveness Analysis of Docetaxel versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Zhen Zhou, Shun Lu, Zhiwei Chen, 2010, Chemotherapy.

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells

W. Xia, Shun Lu, Jiaxiang Shao, 2017, Journal of experimental & clinical cancer research : CR.

Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway

Lin Xu, Jia Huang, Hao Lin, 2015, International Journal of Clinical Oncology.

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.

Yi-long Wu, Jian-hua Chang, Chengping Hu, 2021, Lung cancer.

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).

Ying Cheng, T. Mok, Yi-long Wu, 2020, Lung cancer.

OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

M. Tsuboi, R. Herbst, Yi-long Wu, 2021 .

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

N. Girard, D. Planchard, T. Ciuleanu, 2022, Journal of Clinical Oncology.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

N. Girard, S. Broderick, T. Mitsudomi, 2021 .

Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial

S. Broderick, T. Mitsudomi, Changli Wang, 2021, Clinical Trials.

Ying Cheng, Baolan Li, Yunpeng Liu, 2019, Translational lung cancer research.

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

D. Planchard, Shun Lu, X. Ai, 2021, Frontiers in Oncology.

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.

E. Smit, M. Krzakowski, K. Goto, 2022, Journal of Clinical Oncology.

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Ying Cheng, T. Mok, Yi-long Wu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel

Ying Cheng, Yi-long Wu, B. Han, 2017, ESMO Open.

Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients

Zhen Zhou, M. Liao, Shun Lu, 2012, Journal of surgical oncology.

SIRT6 drives epithelial-to-mesenchymal transition and metastasis in non-small cell lung cancer via snail-dependent transrepression of KLF4

Jia Huang, Q. Luo, Zhiwei Chen, 2018, Journal of experimental & clinical cancer research : CR.

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

S. Ramalingam, M. Saggese, Shun Lu, 2021, Clinical lung cancer.

Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.

Shun Lu, Mengxiao Wang, Yong-feng Yu, 2022, Lung cancer.

Long‐term survival in thymic epithelial tumors: A single‐center experience from China

Shun Lu, X. Ai, S. Shen, 2013, Journal of surgical oncology.

Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.

Yunpeng Liu, Dong Wang, Jie Wang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P1.04-010 CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia

Ying Cheng, Yi-long Wu, Chang-li Wang, 2017 .

OA15.04 Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

D. Camidge, J. Goldman, P. Tomasini, 2021, Journal of Thoracic Oncology.

Effect of ubiquitin carboxy‐terminal hydrolase 37 on apoptotic in A549 cells

X. Niu, Zhiwei Chen, X. Ye, 2011, Cell biochemistry and function.

Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort

G. Lippi, M. Mino‐Kenudson, S. Chuai, 2020, Translational lung cancer research.

Early‐like differentiation status of systemic PD‐1+ CD8 + T cells predicts PD‐1 blockade outcome in non‐small cell lung cancer

Chengping Hu, Jie Zhang, L. Xia, 2022, Clinical & translational immunology.

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Shun Lu, X. Niu, Yuchen Han, 2022, Frontiers in Immunology.

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Ying Cheng, Yi-long Wu, M. Orlando, 2016, Clinical lung cancer.

Regulation of SIRT2 levels for human non-small cell lung cancer therapy.

W. Xia, Shun Lu, Q. Xie, 2013, Lung cancer.

Genomic Alteration During Metastasis of Lung Adenocarcinoma

Jia Huang, Hao Lin, Q. Luo, 2016, Cellular Physiology and Biochemistry.

Polymorphisms of microRNA Sequences or Binding Sites and Lung Cancer: A Meta-Analysis and Systematic Review

Shun Lu, X. Niu, Zhiwei Chen, 2013, PloS one.

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment

L. Xia, Shun Lu, Yingjia Sun, 2022, Journal of clinical medicine.

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Ying Cheng, Yi-long Wu, B. Han, 2018, Translational lung cancer research.

EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer

Xue Wu, Y. Shao, Shun Lu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients

Liu Yang, Xiaowei Yan, H. Herschman, 2021, Proceedings of the National Academy of Sciences.

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial

T. Mok, J. Yang, S. Morita, 2021, JTO clinical and research reports.

The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti‐drug responses in human non‐small cell lung cancer

Shun Lu, X. Niu, Zhiwei Chen, 2014, British journal of pharmacology.

[Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].

Ying Cheng, T. Mok, Yi-long Wu, 2013, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8+ T cells with enhanced effector function and anti-tumor response.

Ying Chen, L. Xia, Shun Lu, 2023, Cell reports.

Lorlatinib for Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer: Primary Efficacy and Safety From a Phase 2 Study in China.

Ying Cheng, C. Bai, He-long Zhang, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

Michael Thomas, E. Felip, S. Shreeve, 2021, Future Oncology.

[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].

Shun Lu, Li Zhang, Yong-feng Yu, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

B. Peil, N. Gibson, Wei Li, 2018, OncoTargets and Therapy.

No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis

Yunhua Xu, L. Gu, Bai-jun Cheng, 2013, Tumor Biology.

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

Jian-hua Chang, Wei Li, Dong Wang, 2020, Cancer medicine.

Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).

T. Yamanaka, M. Ahn, Yi-long Wu, 2016 .

Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer

Ying Cheng, Shun Lu, Kai Wang, 2022, The oncologist.

Angiogenesis in tumorigenesis and the possible rationale for the synergy between angiogenesis inhibitors and CT In 1971

Shun Lu, Shan-Ming Chen, S. Lu, 2015 .

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

Yi-long Wu, Wei Li, Chongrui Xu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism

Jian-min Liu, Shun Lu, Zhu-Gang Wang, 2010, Endocrine.

First-line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic Non–Small Cell Lung Cancer in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

N. Reinmuth, Ying Cheng, E. Felip, 2022, Journal of Thoracic Oncology.

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Ying Cheng, M. Satouchi, He-long Zhang, 2022, International Journal of Clinical Oncology.

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.

W. Wang, Jianxing He, He-long Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.

D. Carbone, E. Felip, L. Paz-Ares, 2023, European journal of cancer.

Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors.

Zhen Zhou, Shun Lu, X. Niu, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

M. Tsuboi, F. de Marinis, M. Tiseo, 2022, ESMO open.

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

A. Marchetti, L. Bubendorf, U. Dafni, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expert consensus on treatment for stage III non‐small cell lung cancer

W. Liang, Jin-Ji Yang, Long Chen, 2023, Medicine Advances.

FBXL5-mediated degradation of single-stranded DNA-binding protein hSSB1 controls DNA damage response

Shun Lu, B. Liu, X. Niu, 2014, Nucleic acids research.

FBXL 5-mediated degradation of single-stranded DNA-binding protein hSSB 1 controls DNA damage response

Shun Lu, X. Niu, B. Liu, 2014 .

Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.

M. Provencio, J. Spicer, Shun Lu, 2020 .

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2020 .

Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial

N. Girard, S. Broderick, T. Mitsudomi, 2022, Cancer Research.

Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.

Shun Lu, S. Qu, Chenwei Cui, 2022, Future oncology.

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component

Yang Xu, Xue Wu, Y. Shao, 2021, Frontiers in Oncology.

Analysis of the T Descriptors and Other Prognosis Factors in Pathologic Stage I Non-small Cell Lung Cancer in China

Chunxiao Wu, M. Liao, Shun Lu, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Resolving an underrepresented circulating tumor cell population in lung cancer enabled by Hexokinase 2 analysis

Xiaowei Yan, H. Herschman, Wei Wei, 2020, bioRxiv.

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison

Shun Lu, Yong-feng Yu, F. Zhu, 2022, Journal of clinical medicine.

Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

M. Liao, X. Hou, Shun Lu, 2010, Lung cancer.

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Shun Lu, Yi Yang, S. Lu, 2019, The oncologist.

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report

Shun Lu, W. Su, Jing Li, 2019, OncoTargets and therapy.

Modelled Economic Analysis for Dacomitinib–A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China

Shun Lu, Lan Gao, L. Luan, 2021, Frontiers in Oncology.

SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo.

B. Liu, Shun Lu, Yi Zhao, 2015, Cellular signalling.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

M. Tsuboi, R. Herbst, F. Shepherd, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation

Jia Huang, Q. Luo, Shun Lu, 2016, Oncotarget.

Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

Wei Wei, Liu Yang, Shun Lu, 2019, Nature Communications.

Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases

Shun Lu, Lei Zhu, Zhengping Ding, 2016, SpringerPlus.

Efficacy and Safety of Anti-Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial.

R. Guo, Shun Lu, Xiangrong Dai, 2023, JTO clinical and research reports.

The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2

Shun Lu, X. Niu, Zhiwei Chen, 2014, FEBS letters.

Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma

Lei Zhu, Shun Lu, Zhengping Ding, 2016, Cancer medicine.

Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients

Shun Lu, Zhiwei Chen, Zheng-bo Song, 2011, Medical oncology.

SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer

B. Liu, Shun Lu, Yi Zhao, 2014, Tumor Biology.

Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer.

M. Liao, Q. Luo, Shun Lu, 2013, Chest.

Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.

Shun Lu, Zhiwei Chen, Yi-fei Zhang, 2009, Chinese medical journal.

Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis

W. Xia, Shun Lu, Jiachen Chen, 2023, Cellular Oncology.

Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104

W. Xia, Ying Yang, Shun Lu, 2020, Oncogene.

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Ping Wang, Ying Cheng, C. Chiu, 2020 .

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

Changli Wang, Jian-hua Chang, Baocheng Wang, 2022, Therapeutic advances in medical oncology.

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial.

Ping Wang, Ying Cheng, C. Chiu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.

Yang Zhang, Ying Cheng, Yi-long Wu, 2014, Lung cancer.

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Shun Lu, Yan Yu, B. Tang, 2022, Cancer journal.

Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

N. Yang, K. Ying, Zhijie Wang, 2020 .

P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

E. Felip, J. Soria, A. Ardizzoni, 2017 .

PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology

L. Sequist, Wenbo Tang, L. Paz-Ares, 2017 .

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial

E. Felip, J. Soria, A. Ardizzoni, 2017 .

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Ying Cheng, Yulan Sun, Sanyuan Sun, 2022, Therapeutic advances in medical oncology.

Prevalence of MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma patients without common targetable mutations: A single-institute study

Jie Zhang, Qing Zhang, S. Lu, 2019, Journal of Cancer Research and Therapeutics.

Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).

Geoffrey Liu, J. Yang, S. Popat, 2021, Future oncology.

Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

C. Chiu, Dong-Wan Kim, G. Chang, 2023, JTO clinical and research reports.

Abstract LB512: RATIONALE-304: The association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)

Yangguang Shi, Zhirong Shen, Yan Yu, 2022, Cancer Research.

Epigenomic analysis of lung adenocarcinoma reveals novel DNA methylation patterns associated with smoking

T. Mok, Q. Tao, Jia Huang, 2013, OncoTargets and therapy.

Isolation and characterization of ex vivo expanded mesenchymal stem cells obtained from a surgical patient

Jia Huang, Q. Luo, Q. Tan, 2014, Molecular medicine reports.

Distribution of NRG1 Gene Fusions in a Large Population of Chinese Patients with NSCLC.

Q. Ou, Shun Lu, Hong-gang Ke, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MA14.05 A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)

Ying Cheng, C. Bai, Jin-Ji Yang, 2019, Journal of Thoracic Oncology.

Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

X. Ai, Jie-jun Wang, S. Shen, 2018, BMC Cancer.

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Haidong Wang, Shun Lu, X. Ai, 2014, Amino Acids.

Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

Shun Lu, Yang Zhang, D. Zhong, 2023, Signal transduction and targeted therapy.

Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis.

X. Ai, Yi Zhao, Yi Yang, 2014, International journal of clinical and experimental pathology.

Molecular epidemiology of EGFR mutations in 7,953 non-small cell lung cancer of Chinese ethnicity.

X. Niu, Zhiwei Chen, D. Ding, 2014 .

Different roles of myofibroblasts in the tumorigenesis of nonsmall cell lung cancer

Jia Huang, Q. Luo, Shun Lu, 2016, Tumor Biology.

A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Kongming Wu, Xun Yuan, Yuling Bao, 2016, International Journal of Nanomedicine.

Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)

K. Goto, Jialei Wang, D. Zhong, 2022, Cancer Research.

Discrepancy of biologic behavior influenced by bone marrow derived cells in lung cancer.

Haiquan Chen, Jing Fang, M. Liao, 2010, Oncology reports.

Rethinking the Status of Chemotherapy Combined With the Addition of Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibition and Programmed Death 1 or Programmed Death-Ligand 1 Blockade.

Shun Lu, Zi-ming Li, S. Lu, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

D. Carbone, E. Felip, L. Paz-Ares, 2021 .

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

M. Socinski, L. Paz-Ares, M. Nishio, 2021 .

S. Lu, Lin Gao, Yong-feng Yu, 2019, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.

Yi-long Wu, Wei Li, Chengping Hu, 2013 .

Maintenance Therapy Improves Survival Outcomes in Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of 14 Studies

Shun Lu, X. Niu, Zhiwei Chen, 2015, Lung.

M. Tsuboi, R. Herbst, Yi-long Wu, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Danyi Wen, Shun Lu, Zhiwei Chen, 2021, Cell biology international.

Establishment of a biomarker model for predicting bone metastasis in resected stage III non-small cell lung cancer

Zhen Zhou, Q. Luo, Shun Lu, 2012, Journal of experimental & clinical cancer research : CR.

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboringMET exon 14skipping alterations (METex14)

Ying Cheng, Yulan Sun, Sanyuan Sun, 2021, Clinical Trials.

Clonal dominance of EGFR and efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC.

X. Yi, Xiaohua Hu, Jiexia Zhang, 2020 .

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness

Q. Geng, Q. Shen, Yan Li, 2019, EBioMedicine.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer

M. Ahn, Yi-long Wu, M. Orlando, 2016, Asia-Pacific journal of clinical oncology.

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion–Positive Non–Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Shun Lu, Jianying Zhou, Chengzhi Zhou, 2023, JCO precision oncology.

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.

Ying Cheng, Jin-Ji Yang, C. Bai, 2020, Lung cancer.

Tagrisso incremental therapy in a case of meningeal metastasis of lung cancer with EGFR mutation: a case report

Shun Lu, X. Ai, Yingjia Sun, 2021, Translational lung cancer research.

Design and implementation of a mobile system for lung cancer patient follow-up in China and initial report of the ongoing patient registry

Xiangyun Ye, Jia Wei, Yun-Qin Chen, 2016, Oncotarget.

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Jie Yang, Ying Cheng, T. Hsia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

A. Chiang, A. Navarro, L. Paz-Ares, 2022, Journal of Clinical Oncology.

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

M. Tsuboi, R. Herbst, F. Shepherd, 2023, The New England journal of medicine.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Keunchil Park, T. Mok, Yi-long Wu, 2018, Lung cancer.

Abstract CT218: Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) for Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870

Ying Cheng, Yi-long Wu, Changli Wang, 2020 .

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis

Jingqi Zhuang, S. Lu, Ziming Li, 2017, Oncotarget.

PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)

Ying Cheng, Yi-long Wu, Chengping Hu, 2017 .

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.

X. Chen, Pengxiang Wu, R. Guo, 2023, The Lancet. Respiratory medicine.

Inhibition of the growth of non-small cell lung cancer by miRNA-1271.

Zhen Zhou, Shun Lu, X. Niu, 2015, American journal of translational research.

Abstract CT031: Preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboringMETexon 14 skipping mutations

Z. Xiaodong, Ying Cheng, He-long Zhang, 2019, Clinical Trials.

Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer.

Y. Guan, C. Zuo, Jun Zhao, 2008, Molecular medicine reports.

XBP1-LOX Axis is critical in ER stress-induced growth of lung adenocarcinoma in 3D culture.

M. Liao, Yi Zhao, Yi Yang, 2017, American journal of translational research.

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

K. O'Byrne, Keunchil Park, T. Mok, 2016 .